NASDAQ:QURE uniQure (QURE) Stock Price, News & Analysis $25.61 +0.64 (+2.57%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About uniQure Stock (NASDAQ:QURE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get uniQure alerts:Sign Up Key Stats Today's Range$24.60▼$25.9550-Day Range$20.97▼$51.0552-Week Range$8.73▼$69.99Volume217,150 shsAverage Volume2.39 million shsMarket Capitalization$1.78 billionP/E RatioN/ADividend YieldN/APrice Target$53.25Consensus RatingModerate Buy Company Overview uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease. uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement. The company also has a clinical-stage pipeline that has included AMT-130, an investigational gene therapy for Huntington’s disease, as well as other programs targeting neurological and neuromuscular disorders. The company was founded in the Netherlands in 1998 as Amsterdam Molecular Therapeutics and adopted the uniQure name in 2012. It maintains operations in the United States and Europe, with research, development and manufacturing capabilities serving its global programs. uniQure is headquartered in Lexington, Massachusetts, and its ordinary shares trade on the Nasdaq Global Select Market under the symbol QURE.AI Generated. May Contain Errors. Read More uniQure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreQURE MarketRank™: 3.48747093774 of 5 starsuniQure scored higher than 70% of companies evaluated by MarketBeat, and ranked 263rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatinguniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 1 strong buy rating, 12 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialuniQure has a consensus price target of $53.25, representing about 113.3% upside from its current price of $24.97.Amount of Analyst CoverageuniQure has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about uniQure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for uniQure are expected to grow in the coming year, from ($3.82) to ($3.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of uniQure is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of uniQure is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiouniQure has a P/B Ratio of 7.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about uniQure's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.19% of the float of uniQure has been sold short.Short Interest Ratio / Days to CoveruniQure has a short interest ratio ("days to cover") of 3.84, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in uniQure has recently increased by 0.12%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YielduniQure does not currently pay a dividend.Dividend GrowthuniQure does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.79 News SentimentuniQure has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for uniQure this week, compared to 10 articles on an average week.Search Interest10 people have searched for QURE on MarketBeat in the last 30 days. MarketBeat Follows4 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, uniQure insiders have not sold or bought any company stock.Percentage Held by Insiders4.65% of the stock of uniQure is held by insiders.Percentage Held by Institutions78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about uniQure's insider trading history. Receive QURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QURE Stock News HeadlinesuniQure (QURE) Stock Could Be Overvalued Despite A Securities Investigation2 hours ago | finance.yahoo.comuniQure to Report Third Quarter 2026 Financial Results on November 4, 2026October 28 at 7:31 AM | quiverquant.comQElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he says is the same size Nvidia was a decade ago. The company holds 150 patents protecting its core technology, and Brown believes Elon Musk could soon drive major demand for it. A key catalyst is set for November 11.October 29 at 1:00 AM | Brownstone Research (Ad)uniQure to Announce Third Quarter 2026 Financial ResultsOctober 28 at 7:05 AM | globenewswire.comAnalyzing CollPlant Biotechnologies (NASDAQ:CLGN) and uniQure (NASDAQ:QURE)October 27 at 7:27 AM | americanbankingnews.comuniQure N.V. (NASDAQ:QURE) Stock Has Average Price Target of $53.25October 21, 2026 | americanbankingnews.comHead-To-Head Review: ProKidney (NASDAQ:PROK) versus uniQure (NASDAQ:QURE)October 19, 2026 | americanbankingnews.comuniQure: The Market Graded The Wrong ExamOctober 15, 2026 | seekingalpha.comSee More Headlines QURE Stock Analysis - Frequently Asked Questions How have QURE shares performed this year? uniQure's stock was trading at $23.93 at the beginning of the year. Since then, QURE stock has increased by 4.3% and is now trading at $24.97. How were uniQure's earnings last quarter? uniQure N.V. (NASDAQ:QURE) issued its quarterly earnings results on Wednesday, July, 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.40. The biotechnology company earned $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. uniQure had a negative trailing twelve-month return on equity of 111.96% and a negative net margin of 1,350.73%. Read the conference call transcript. When did uniQure IPO? uniQure (QURE) raised $76 million in an IPO on Wednesday, February 5th 2014. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Who are uniQure's major shareholders? Top institutional investors of uniQure include Two Seas Capital LP (1.91%), Assenagon Asset Management S.A. (1.00%), Maxi Investments CY Ltd (0.06%) and Sanders Morris Harris LLC (0.03%). Insiders that own company stock include Matthew C Kapusta, Christian Klemt, Walid Abi-Saab, Jeannette Potts, Kylie O'keefe, Pierre Caloz, Madhavan Balachandran, Jeremy P Springhorn, David D Meek, Leonard E Post, Rachelle Suzanne Jacques, Robert Gut and Jack Kaye. View institutional ownership trends. How do I buy shares of uniQure? Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of uniQure own? Based on aggregate information from My MarketBeat watchlists, some other companies that uniQure investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Salesforce (CRM), Tesla (TSLA) and Intel (INTC). Company Calendar Last Earnings7/29/2026Today10/29/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 QURE's financial health is in the Yellow zone, according to TradeSmith. QURE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:QURE CIK1590560 Webwww.uniqure.com Phone(120) 240-6000Fax31-20-566-9272Employees221Year Founded1868Price Target and Rating Average Price Target for uniQure$53.25 High Price Target$80.00 Low Price Target$28.00 Potential Upside/Downside+108.5%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.97 million Net Margins-1,350.73% Pretax Margin-1,313.04% Return on Equity-111.96% Return on Assets-29.01% Debt Debt-to-Equity Ratio0.15 Current Ratio10.01 Quick Ratio10.01 Sales & Book Value Annual Sales$18.67 million Price / Sales94.86 Cash FlowN/A Price / Cash FlowN/A Book Value$3.19 per share Price / Book8.00Miscellaneous Outstanding Shares69,366,000Free Float66,140,000Market Cap$1.77 billion OptionableOptionable Beta1.06 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:QURE) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredThe cash in your checking account has a problemThere's a pile of cash sitting in your checking account, earning next to nothing while you weigh your options....Counterflow | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
